Moreover, survival analysis subtypes from the Kaplan‒Meier Plotter database [31] showed that high ATP6AP1 expression was associated with poor patient outcomes in luminal breast cancer, while it was insignificant in HER2+ or basal (Fig. 1H), consistent with findings from the bc-GenExMiner tool (Fig. S1A). This evidence concerns the gene ATP6AP1 and breast carcinoma.